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Abstract
Purpose Evidence supporting the use of therapeutic
intra-articular facet joint injections for patients with sus-
pected facet joint pain is sparse. A systematic review
including a narrative synthesis was carried out to determine
if intra-articular facet joint injections with active drug are
more effective in reducing back pain and back pain-related
disability than a sham procedure or a placebo/inactive
injection. Secondly, to determine if intra-articular facet
joint injections with active drug or placebo/inactive
injection are more effective in reducing back pain and back
pain-related disability than conservative treatment.
Methods Medline, EMBASE, CINAHL, CENTRAL,
Index to Chiropractic Literature and the Cochrane Central
Register of Controlled Trials were searched from inception
through April 2015. Data were screened and single
extraction with independent verification and risk of bias
assessment was performed.
Results A total of 391 records were screened, and six
trials were included. The trials included were small (range
18–109 participants) and overall in terms of pain and dis-
ability outcomes most were inconclusive. Only two of the
trials report any significant between-group differences in
pain (mean difference -1.0, 95 % CI -2.0 to -0.1) and
(p = 0.032) or disability (mean difference -3.0, 95 % CI
-6.2 to 0.2) and (p = 0.013) outcomes.
Conclusions The studies found here were clinically
diverse and precluded any meta-analysis. A number of
methodological issues were identified. The positive results,
whilst interpreted with caution, do suggest that there is a
need for further high-quality work in this area.
Keywords Systematic review  Intra-articular facet joint
injections  Low back pain  Disability
Background
Low back pain continues to be responsible for more years
lived with disability than any other disorder [1]. Multiple
international studies attest to the massive health care and
societal costs of low back pain [2]. Most of those affected
have non-specific low back pain [3].
Low back pain can arise from the synovial facet joints
[4]. Facet joint injury can occur from mechanical damage
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due to compressive forces or extensive stretching; degen-
erative changes such as osteoarthritis and inflammatory
processes including rheumatoid arthritis [5, 6]. Facet joints
are richly innervated by the medial branches from the
dorsal rami above and below each joint [7]. The proportion
of people affected by low back pain for whom facet joint
pain is a contributing factor is unclear. In an interventional
pain management practice study the prevalence of chronic
back pain being caused by facet joints was reported to be
31 % [8].
It is plausible that people whose low back pain is arising,
at least in part, from facet joints is a sub-group for whom
specific local treatment might be effective. The role of
interventional procedures, such as intra-articular facet joint
injections, in themanagement of low back pain is not clear. It
is intra-articular injections for facet joint pain that are the
focus of this review. Guidelines in both the UK and USA
have not supported the use of intra-articular facet joint
injections because of the absence of evidence to support their
use [3, 9, 10]. Nevertheless, they are still widely used. Pre-
vious reviews of interventional procedures for low back pain
have included multiple procedures and some have included
both diagnostic and therapeutic injections. To aid our
understanding of the possible role of intra-articular facet
joint injection we have, in this review, focussed just on
therapeutic intra-articular facet joint injections and have
extended our interpretation to include consideration of the
different populations recruited and differences in the com-
parator groups in our excluded studies.
Corticosteroids are established anti-inflammatory agents
with demonstrable, short-term, benefits when injected
intra-articularly to treat shoulder impingement syndrome or
osteoarthritis of peripheral joints [11–15]. Intra-articular
corticosteroid injections are beneficial in rheumatoid
arthritis and have been shown to provide symptomatic
relief for up to 3 months duration [16].
At a molecular level, corticosteroids may alter the
transcription of pro-inflammatory genes [17]. The pain may
originate from an inflammatory process occurring within
the synovial joint or on the articular surfaces of the facet
joints [18]. By reducing the levels of inflammation in or
around the facet joint, there will be a reduction in the
release of inflammatory mediators, which may be acting
directly on the receptors or sensitising them to provoke a
response.
With the success of corticosteroid injections in other
joints and a firm knowledge of the mechanism of action of
corticosteroids, it is reasonable to hypothesise that the same
benefit could be delivered in another synovial joint, i.e. the
facet joints. Furthermore, any symptom relief may facili-
tate adherence to physiotherapy or an exercise programme
designed to improve lumbar range of movement and
muscular stability [19].
Interpreting research data on treatment for facet joints
needs to take into account how the exact research question
being addressed impacts on study design and interpretation of
the results. There are substantial challenges in arriving at a
clinical diagnosis of probable facet joint pain; and hence, who
should be considered for facet joint injections [20]. For a
confirmed diagnosis, a positive diagnostic injection of local
anaesthetic is required [21]. For studies of treatments for facet
joint injections either clinical assessment or a positive diag-
nostic procedure can be used to define entry criteria. Intra-
articular facet joint injections can be evaluated pragmatically
by testing their effectiveness when they are compared with a
conservative treatment (or no treatment). Alternatively they
can be evaluated in more explanatory studies where they are
compared to a placebo control or to a sham procedure.
We report a systematic review of randomised controlled
trials of therapeutic intra-articular lumbar facet joint
injections.
Specifically our objectives were:
1. To determine if facet joint injections with active drug
are more effective in reducing back pain and back
pain-related disability than a sham procedure or a
placebo/inactive injection.
2. To determine if facet joint injections with active drug
or placebo/inactive injection are more effective in
reducing back pain and back pain-related disability
than conservative treatment.
Methods
Types of studies
We prospectively registered our systematic review with the
International Prospective Register of Systematic Reviews
(PROSPERO) (CRD42015018991) http://www.crd.york.ac.
uk/PROSPERO/display_record.asp?ID=CRD42015018991.
We only included RCTs of therapeutic interventions; we
excluded studies of diagnostic injections alone.
Types of participants
Male and female patients aged 18 or over reporting
symptoms of acute (\6 weeks), sub-acute (6–12 weeks), or
chronic (12 weeks or more) back pain.
Types of interventions
We only included studies on injections into or around the
facet joints. Injections into other areas were excluded.
Sham procedures were defined as any procedure whereby
the participant had believed a corticosteroid had been
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injected into their facet joints. This may include inserting a
needle into the facet joint, but not injecting a substance or
using a device to replicate the sensation of a needle.
A placebo was defined as being any inert substance
injected into or around the facet joint which may include
saline.
Conservative therapy included the following
interventions:
• Oral or topical medications.
• Corticosteroid injections other than into the facet joints.
• Physical therapies including exercise (supervised or
unsupervised), acupuncture, and manual treatments
(osteopathy and chiropractic).
• Psychological interventions including cognitive-be-
havioural therapy (CBT).
A sham facet joint injection and a corticosteroid injec-
tion delivered other than to the facet joints was considered
to be a sham procedure. Injection of corticosteroid deliv-
ered other than to a facet joint without a sham facet joint
injection was considered as conservative treatment.
Types of outcome measures
We considered trials reporting at least one of the following:
• Symptom relief based on pain.
• Back specific functional status (disability).
We included trials that included outcomes for short term
(4 weeks), medium term (3 months) and long term
(6 months or longer). Where there are other outcomes
listed, we selected the closest matching to our categories.
We considered the following outcomes:
• Pain—measured by Visual Analogue Scale (VAS),
Numerical Rating Scale (NRS) or McGill pain ques-
tionnaire or similar.
• Disability—measured by Oswestry disability index
(ODI), Roland–Morris disability questionnaire
(RMDQ), Million VAS disability score or Sickness
Impact Profile (SIP) or similar.
We considered the following secondary outcomes:
• Adverse events.
Search methods for identification (electronic/other
resources)
We used the search strategy developed by the Cochrane
Back Review Group [22] and Chapter six ‘Searching for
Studies’ of the Cochrane Handbook [23].
The following databases were searched for relevant
studies:
• Medline
• EMBASE
• CINAHL
• CENTRAL
• Index to chiropractic literature
In addition, citation tracking of the studies retrieved by
the search was conducted until no new studies were found.
Ongoing trials were identified through the WHO Interna-
tional Clinical Trials Registry Platform (http://www.who.
int/ictrp/en/) and ClinicalTrials.gov websites. Details of the
search strategies are provided in the appendices (Appendix
1, available online as Supplemental Digital Content…).
Data collection and analyses
For each of the steps the two reviewers (RV, RB) inde-
pendently selected studies, assessed the risk of bias,
extracted data and resolved differences by consensus
bringing in a third review author (HS or DE) when dis-
agreements persisted.
Selection of studies
The two review authors screened the titles and abstracts
after which the full text of potentially relevant studies were
then retrieved for the final selection of eligible studies.
Data extraction and management
The two review authors independently extracted the data
using standardised data extraction forms. The following
information was collected:
• Study characteristics (aims of the study, study design,
randomisation).
• Population characteristics—(patient population source
or setting, study inclusion and exclusion criteria,
duration of low back pain, diagnostic criteria, age,
sex, country).
• Intervention characteristics—(description and types of
corticosteroid, dose).
• Comparator characteristics—(description of compara-
tor, duration, frequency).
• Outcome data—(pain intensity and disability at short
term, medium term and long term).
• Number of participants assessed, number of dropouts.
• Statistical methods and results.
• Adverse events.
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Assessment of risk of bias in included studies
Two review authors independently assessed the risk of
bias. Disagreements that could not be resolved were
referred to a third review author (HS). The risk of bias
assessment tool recommended by The Cochrane Collabo-
ration [23, 24] and the Cochrane Back Review Group’s
updated method guidelines [22] were used. Studies were
characterised as ‘Low Risk’, ‘High Risk’, or ‘Unclear Risk’
of bias for each of the criteria. A study with a low risk of
bias was defined as having low risk on six or more of the
items and no fatal flaws. A study was defined as having
unclear risk of bias if one or more of the criteria did not
have enough information.
Data synthesis
Heterogeneity between the included studies was explored
by looking at the methodologies and outcomes being
considered. We planned, where possible, to do meta-anal-
yses. Heterogeneity in how the research questions were
framed meant this was not possible. As such, we present a
narrative synthesis of the available data.
Results
We identified 507 articles from electronic databases and an
additional 24 from related systematic reviews. After
removal of duplicates there were 393 unique articles which
were screened for inclusion. We retrieved 42 full papers;
36 of these were excluded leaving six included studies. See
Fig. 1. PRISMA flow diagram [25].
Included studies
We included six trials with a total of N = 434 participants
(range 18–109 participants); Lilius [26], Carette [27],
Mayer [28], Celik [29], Kawu [30] and Ribeiro [31].
The inclusion criteria were variable (Table 1). Two tri-
als (Carette [27], Mayer [28]) included a diagnostic
injection, into the facet joints, one trial, (Ribeiro [31]) used
a combination of clinical and radiological assessment. The
remaining three Lilius [26], Celik [29], and Kawu [30]
used a clinical assessment only. The inclusion criteria fall
under four broad headings these are: pain intensity or
duration, physical tests, diagnostic tests, or more general
criteria (see Table 1).
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Injection procedures and injectate
All six trials used different injection procedures with
variations in the number of joints injected and whether they
are injected unilaterally or bilaterally. Lilius [26] had two
intervention groups who either had injections into the facet
joints (intra-articular) or injections ‘around’ the facet joints
(peri-capsular). These two groups were pooled for the final
comparison.
The injectate used varied in volume and content. Three
trials used a combination of bupivacaine hydrochloride
(local anaesthetic) and methyl-prednisolone (corticos-
teroid) in various volumes and concentrations (Lilius [26],
Celik [29], Kawu [30]). Carette used a combination of
methyl-prednisolone and saline (no local anaesthetic).
Mayer et al. used a combination of bupivacaine and a non-
specified depot preparation corticosteroid. Ribeiro [31]
used a combination of triamcinolone hexacetonide and
lidocaine (Table 1).
Sham/placebo controls
Two trials Lilius [26] and Carette [27] used intra-articular
saline as a placebo control, whilst Ribeiro [31] used active
injections into para-spinal muscles as a sham control.
Conservative treatments
Three trials include a ‘conservative treatment’ as a control.
One was a drug regime and at least 4 days bed rest (Celik
[29]). In the other two trials the control treatment was a
physical therapy one based on a McKenzie regime (Kawu
[30]) and the other, facility based, exercises and advice to
use stretching exercises at home (Mayer [28]). Two trials,
Celik [29] and Kawu [30], used conservative treatment as
an alternative to injections whilst Mayer [28] added
injections to conservative treatment.
Two of the trials included a sample size calculation for
their primary outcomes (Carette [27], Ribeiro [31]). Rea-
son for incomplete follow-up was not reported in one study
(Carette [27]), four studies had no loss at follow-up (Lilius
[26], Mayer [28], Celik [29], Kawu [30]), one study
(Ribeiro [31]) reported four dropouts, three missed follow-
up and one, in the intervention group, died (not related to
study).
Three trials reported adverse events. Lilius et al. [26],
reported ‘few’ side effects but do not specify what they
were. Carette et al. [27], report some localised pain near
injection site. Ribeiro et al. [31] report adverse events,
noting there were no significant differences between
groups. These included; post-procedure pain (n = 9),
cutaneous hypochromia (n = 1), increase in blood glucose
levels (n = 5), vaginal bleeding (n = 3), dizziness (n = 3)
and nausea (n = 3). In addition, one control group patient
had a serious adverse event; gastrointestinal bleeding,
which required endoscopic therapy. They also note that one
patient in the intervention group had a fall after a follow-up
visit that caused an aggravation of the patient’s back pain.
Excluded studies
We excluded 36 studies which included Kennedy, 2013
and Hayes, 2006 which were excluded as there was only an
abstract available [32, 33]. Contact was made with the lead
author of the Kennedy paper who is in the process of
submitting a manuscript. Brief details of the excluded
studies are provided in the appendices (Appendix 2,
available online as Supplemental Digital Content…).
Measures of outcome (i.e. pain and disability)
All six of the trials report on pain and disability outcomes
(Table 2). All six of the trials used a visual analogue scale
for pain, some of these are well defined with anchors
described but others are less specific. Carette, also included
the McGill pain questionnaire from which the ‘mean pre-
sent pain intensity’ was taken as the variable of interest for
this review.
Disability was measured with a variety of tools. Two
trials included the Oswestry Disability Questionnaire with
the first noting that they used a modified version and the
second quotes they used the ‘Oswestry disability index’
(Celik [29], Kawu [30]). The four remaining trials all used
different tools: Lilius et al. uses an undefined measure
based on six physical actions; Carette et al. used a modified
Sickness Impact Profile (SIP) measure with two of the
original variables removed (eating and communicating);
Mayer et al. used the Million VAS, a visual analogue scale
based on 15 questions related to activities of daily living,
and finally Ribeiro et al. used a Roland–Morris Disability
Questionnaire (Table 2).
Length of follow-up
End of follow-up was between 5 and 7 weeks in Mayer,
3 months in Lilius, 24 weeks in Ribeiro and 6 months in
Carette, Celik and Kawu (Table 2).
Quality assessment profiles
Figure 2 includes a quality assessment profile for each of
the included trials. These are summarised below.
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Allocation (selection bias)
There was generally low-risk allocation bias across all
studies with concealment maintained. However, there were
two studies from which it was not possible to determine
risk of allocation bias as there was no description of the
process. One study (Mayer) was at high risk of allocation
bias as patients were allocated to the two groups in an
alternating manner (see Fig. 2).
Blinding (performance bias and detection bias)
One study (Lilius) was unclear on its method of blinding
and whether participants were truly blinded to what they
were receiving.
In Carette’s study, the participants were blinded as to
which treatment they were receiving with the syringe
covered in tin foil for both control and intervention. The
care providers and assessors were also blinded.
Celik et al. had high risk of blinding bias due to the
control being exercise or physiotherapy, the participants
could not be blinded to the process.
Ribeiro was partially blinded with the participants;
however, the care providers were not blinded as they were
injecting the control and treatment in different anatomical
sites.
Incomplete outcome data (attrition bias)
In two studies (Lilius and Carette) there were patients who
did not attend the follow-up examination post-treatment;
however, this was deemed to be insignificant to the out-
comes drawn by the paper as they were from both the
control and intervention groups. Similarly, in another study
(Ribeiro), there was low risk of attrition bias as equal
numbers were lost from the control and intervention
groups. Celik et al. studies were low risk as no patients left
the study.
Selective reporting (reporting bias)
These are generally low risk across the studies with the pre-
specified set of outcomes being reported.
Effects of interventions
Here we present the outcomes of the trials split into two
categories, which are:
• Injection versus sham control.
• Injection versus conservative treatment control.
Those including a diagnostic injection will be high-
lighted. Understanding how differences in participant
selection, and the comparators used in these trials is critical
to understanding how the results might be interpreted and
where data pooling might be possible. We have sought to
clarify the differences and similarities in Fig. 3.
Below we summarise the outcome findings from the
trials details can be found in Table 2.
Injection versus sham control (pain and disability
outcomes)
Three trials have an injection verses a sham injection
control (Lilius [26], Carette [27], Ribeiro [31]) with one
(Carette [27]) using a diagnostic injection before ran-
domisation (Table 2a). In the Carette trial 190 patients
were given the diagnostic injection (lidocaine), 110
Lilius 
1989 
Caree 
1991 
Mayer 
2004 
Celik 
2011 
Kawu 
2011 
Ribeiro 
2013 
Random Sequence Generaon 
Allocaon concealment 
Blinding of parcipants 
Blinding of personnel/care providers 
Blinding of outcomes assessors 
Incomplete outcome data 
Selecve outcome reporng 
Group similarity at baseline 
Co-intervenons 
Compliance 
Intenon-to-treat analysis 
Timing of outcome assessments 
Other bias 
Key:   Unclear risk of bias.    Low risk of bias.    High risk of bias. 
Fig. 2 Risk of bias assessments
for included trials
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patients met the inclusion criterion of a 50 % or more
reduction in pain, two of these had no recurrence of pain
and seven chose not to participate. Therefore, 101 patients
entered the randomised phase (intervention, n = 51, pla-
cebo, n = 50). Four patients, two in each arm, were later
excluded from analysis for not meeting inclusion criteria.
None of these trials report significant differences in pain
or disability between groups at their pre-specified primary
outcome. Carette [27] reports significant between-group
differences in the visual analogue pain score (mean dif-
ference -1.0, 95 % CI -2.0 to -0.1) and the sickness
impact profile (physical dimension) (mean difference -3.0,
95 % CI -6.2 to 0.2) at final follow-up (6 months) [27].
Ribeiro report statistically significant differences in role
physical sub-scale of SF-36 over 24 weeks (p = 0.023),
‘improvement percentage’ at 1 and 24 weeks (p = 0.03
and p = 0.04), pain improvement at week one (p = 0.029),
Diclofenac use (p = 0.04), and Roland–Morris Disability
score at 12 weeks (p = 0.01) [31].
Injection versus conservative treatment control (pain
and disability outcomes)
Three trials have injection verses a conservative treatment
(Mayer [28], Celik [29], Kawu [30]) with one (Mayer [28])
using a diagnostic injection (see Table 2b). One trial
(Mayer [28]) reports no significant differences between
groups for either pain or disability at follow-up
(5–7 weeks). The results in the Kawu trial are presented
within group, but they do state that there was a significant
between-group improvements in pain (intervention, males,
mean 4.1 ± 1.7, females 3.9 ± 1.2 and control males
Fig. 3 Summary of designs of
included studies. Entry criteria;
clinical clinical assessment
only, radiographic clinical plus
radiological change, block
clinical plus positive diagnostic
block, acute pain\3 months,
chronic pain more than
3 months: interventions, LA
local anaesthetic, NSAID non-
steroidal anti-inflammatory
drugs, McKenzie McKenzie
exercise technique
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5.2 ± 1.3, females 4.8 ± 1.9, p = 0.032) at 6-month fol-
low-up. For disability outcomes they report a significant
improvement over time (p = 0.013) [30]. Celik [29] only
report within-group data; there are no between-group
results reported (Table 2).
Discussion
Our systematic review revealed that there were few trials of
intra-articular facet joint injections. That no two trials have
tested similar hypotheses means it is difficult to draw any
clinically useful conclusions.
There is a wide range in the quality of the six trials
reported here. Only two, (Carette [27], Ribeiro [31])
reported a sample size calculation, and had clear infor-
mation on randomisation and only one of these provided
information about allocation-concealment [31].
There is no consistent pattern of benefit across trials.
Some show levels of improvement whilst others find none.
Indeed, patients improve with and without the intervention
treatment. In the Lilius study, they found there was
improvement in pain and disability across all three inter-
vention groups [26]. Similarly, in the Ribeiro trial both
treatments are found to be equally effective with only a
slightly larger improvement following intra-articular ster-
oids over intramuscular injections in some secondary out-
comes; but without a consistent pattern. Both groups were
found to have improvement with regard to functional sta-
tus; however, the difference between them was not statis-
tically significant until week 12. The co-intervention intake
was significantly different between the two groups with
diclofenac intake reduced in the experimental group [31].
Mayer suggests that corticosteroid injections in con-
junction with supervised stretching exercises may improve
pain or disability outcomes rather than exercise alone.
However, they concluded that facet joint injections do not
explain the improved pain and disability outcomes
observed in the control and treatment groups as the pre-
and post-trial measures were comparable and therefore
could not be attributed to the pharmacological profile of the
cortisone taking effect. Even though the range of lumbar
movement was observed to be significantly improved in the
treatment group. The study also stated possible bias due to
the difference in segmental rigidity of participants between
both groups despite randomisation, but due to the range of
movements being opposite in both groups, they disregarded
this as a potential source of bias [28].
The Kawu trial does report a positive significant result
for both pain and disability outcomes at 6 months [30]. The
control, conservative treatment, in this trial was physio-
therapy (McKenzie technique) this technique encourages
extension of the back. There is now a growing body of
evidence that this will just make the pain worse for those
with chronic low back pain particularly those with facet
joint pain. Thus it maybe that the lack of improvement in
pain and disability outcomes in the control group was due
to exacerbation of the patients back pain problems by the
exercises given [34].
Overall completeness of evidence in terms of applica-
bility, from the current evidence, does not support the use
of intra-articular facet joint injections. However, as statis-
tically significant between-group differences are reported
in some secondary outcomes (all favouring intervention) in
some of the studies there is merit in further investigating
their potential effectiveness.
In the majority of studies presented in this review, no
adverse events or side effects associated with the treat-
ments were reported. Transient symptoms such as
increased low back discomfort were noted though most
trials were small and not designed to evaluate adverse
events, so no clear conclusion can be drawn regarding the
risks of facet joint injections. It is important that future
trials record any adverse events while using these proce-
dures in order to appropriately weigh any benefits against
potential risks.
It is possible that in searching studies for this review,
relevant but unpublished trials may have been missed,
which are often likely to be small studies without positive
results, leading to publication bias. However, because the
majority of published trials was small and did not show a
positive effect, publication bias does not seem to be a big
problem in this review.
Due to the study selection criterion used, including only
trials of intra-articular facet joint injections, this review
included fewer studies than similar reviews [9, 35]. Many
excluded RCTs used different types of injection therapy
and denervation procedures. However, the main conclu-
sions of our review appear to be similar to recent system-
atic reviews, which generally report a paucity of high-
quality RCTs on injection therapy for lower back pain and
insufficient evidence to support their use.
Conclusions
Facet joint injections are commonly used; however, there is
insufficient high-quality evidence to support their usage
over placebo/sham-controlled procedures or conservative
therapy for lower back pain. Further investigations are
required to prove their efficacy in targeting lower back
pain, which is attributed to facet joints and this must be
balanced against any potential adverse events as a result of
the injections.
Further randomised controlled trials of higher method-
ological standard comparing facet joint injection with a
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sham/placebo control or conservative treatment are needed
from which to base any conclusion on the effectiveness of
facet joints in improving pain and disability outcomes.
Acknowledgments This project benefited from facilities funded
through Birmingham Science City Translational Medicine Clinical
Research and Infrastructure Trials Platform, with support from
Advantage West Midlands. The team wish to acknowledge the NIHR
(HTA Project: 11/31/01—Facet Feasibility) whilst not funding this
project the grant is covering the salary of one of the team (DE).
Compliance with ethical standards
Conflict of interest MU is principal investigator and HS is a co-
investigator for a trial exploring the feasibility on doing a randomised
controlled trial testing the addition of intra-articular facet joint
injections to best usual care (HTA Project: 11/31/01—Facet Feasi-
bility). DE is also working on this trial as a researcher. The other
authors report no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M,
Shibuya K, Salomon JA, Abdalla S, Aboyans V et al (2012) Years
lived with disability (YLDs) for 1160 sequelae of 289 diseases and
injuries 1990–2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 380(9859):2163–2196. doi:10.1016/
S0140-6736(12)61729-2
2. Dagenais S, Caro J, Haldeman S (2007) A systematic review of low
back pain cost of illness studies in the United States and interna-
tionally. Spine J 8(1):8–20. doi:10.1016/j.spinee.2007.10.005
3. NICE (2009) Low back pain: early management of persistent
non-specific low back pain. National Institute for Health and Care
Excellence. https://www.nice.org.uk/guidance/cg88/resources/
guidance-low-back-pain-pdf. Accessed 08 Aug 2015
4. Manchikanti L, Singh V (2002) Review of chronic low back pain
of facet joint origin. Pain Physician 5(1):83–101
5. Lewinnek GE, Warfield CA (1986) Facet joint degeneration as a
cause of low back pain. Clin Orthop 213:216–222
6. Dreyfuss PH, Dreyer SJ, Herring SA (1995) Lumbar zygapo-
physial (facet) joint injections. Spine 20(18):2040–2047
7. Bogduk N, Wilson AS, Tynan W (1982) The human lumbar
dorsal rami. J Anat 134(Pt 2):383–397
8. Manchikanti L, Boswell MV, Singh V, Pampati V, Damron KS,
Beyer CD (2004) Prevalence of facet joint pain in chronic spinal
pain of cervical, thoracic, and lumbar regions. BMC Muscu-
loskelet Disord 5(15):15. doi:10.1186/1471-2474-5-15
9. Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ,
Baisden J, Carragee EJ, Grabois M, Murphy DR, Resnick DK,
Stanos SP, Shaffer WO, Wall EM (2009) Interventional therapies,
surgery, and interdisciplinary rehabilitation for low back pain: an
evidence-based clinical practice guideline from the American
Pain Society. Spine 34(10):1066–1077. doi:10.1097/BRS.
0b013e3181a1390d
10. Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell MV,
Buenaventura RM, Bryce DA, Burks PA, Caraway DL, Calodney
AK et al (2013) An update of comprehensive evidence-based
guidelines for interventional techniques in chronic spinal pain.
Part II: guidance and recommendations. Pain Physician 16(2
Suppl):S49–S283
11. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G
(2006) Intraarticular corticosteroid for treatment of osteoarthritis
of the knee. Cochrane Database Syst Rev 2:CD005328
12. Buchbinder R, Green S, Youd JM (2003) Corticosteroid injec-
tions for shoulder pain. Cochrane Database Syst Rev
1:CD004016
13. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther
KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kakla-
manis P, Leeb B, Lequesne M, Lohmander S, Mazieres B,
Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B,
Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M,
Therapeutics ESCfICSI (2005) EULAR evidence based recom-
mendations for the management of hip osteoarthritis: report of a
task force of the EULAR Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum
Dis 64(5):669–681
14. Machado E, Bonotto D, Cunali PA (2013) Intra-articular injec-
tions with corticosteroids and sodium hyaluronate for treating
temporomandibular joint disorders: a systematic review. Dental
Press J Orthod 18(5):128–133
15. Colen S, Geervliet P, Haverkamp D, Van Den Bekerom MP
(2014) Intra-articular infiltration therapy for patients with
glenohumeral osteoarthritis: a systematic review of the literature.
Int J Shoulder Surg 8(4):114–121. doi:10.4103/0973-6042.
145252
16. van Vliet-Daskalopoulou E, Jentjens T, Scheffer RT (1987) Intra-
articular rimexolone in the rheumatoid knee: a placebo-con-
trolled, double-blind, multicentre trial of three doses. Br J
Rheumatol 26(6):450–453
17. Barnes PJ, Adcock I (1993) Anti-inflammatory actions of ster-
oids: molecular mechanisms. Trends Pharmacol Sci 14(12):
436–441
18. Kidd BL, Morris VH, Urban L (1996) Pathophysiology of joint
pain. Ann Rheum Dis 55(5):276–283
19. Jack K, McLean SM, Moffett JK, Gardiner E (2010) Barriers to
treatment adherence in physiotherapy outpatient clinics: a sys-
tematic review. Man Ther 15(3):220–228. doi:10.1016/j.math.
2009.12.004
20. Mars T, Ellard D, Antrobus J, Cairns M, Underwood M, Hay-
wood K, Keohane S, Sandhu H, Griffiths F (2015) Intraarticular
facet injections for low back pain: design considerations, con-
sensus methodology to develop the protocol for a randomized
controlled trial. Pain Physician 18(5):473–493
21. Sehgal N, Dunbar EE, Shah RV, Colson J (2007) Systematic
review of diagnostic utility of facet (zygapophysial) joint injec-
tions in chronic spinal pain: an update. Pain Physician
10(1):213–228
22. Furlan AD, Pennick V, Bombardier C, van Tulder M, Editorial
Board CBRG (2009) 2009 updated method guidelines for sys-
tematic reviews in the Cochrane Back Review Group. Spine
34(18):1929–1941. doi:10.1097/BRS.0b013e3181b1c99f
23. Higgins JPT GSe (2011) The Cochrane collaboration, 2011.
Cochrane Handbook for Systematic Reviews of Interventions
Version 510. Available from www.cochrane-handbook.org.
Accessed March 2011
24. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman
AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias
Methods G, Cochrane Statistical Methods G (2011) The
Cochrane collaboration’s tool for assessing risk of bias in ran-
domised trials. BMJ 343:d5928. doi:10.1136/bmj.d5928
Eur Spine J
123
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009)
Preferred reporting items for systematic reviews and meta-anal-
yses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.
b2535
26. Lilius G, Laasonen EM, Myllynen P, Harilainen A, Gronlund G
(1989) Lumbar facet joint syndrome: a randomised clinical trial.
J Bone Joint Surg Br 71(4):681–684
27. Carette S, Marcoux S, Truchon R, Grondin C, Gagnon J, Allard
Y, Latulippe M (1991) A controlled trial of corticosteroid
injections into facet joints for chronic low back pain. N Engl J
Med 325(14):1002–1007
28. Mayer TG, Gatchel RJ, Keeley J, McGeary D, Dersh J, Anag-
nostis C (2004) A randomized clinical trial of treatment for
lumbar segmental rigidity. Spine 29(20):2199–2205
29. Celik B, Er U, Simsek S, Altug T, Bavbek M (2011) Effective-
ness of lumbar zygapophysial joint blockage for low back pain.
Turk Neurosurg 21(4):467–470
30. Kawu AA, Olawepo A, Salami AO (2011) Facet joints infiltra-
tion: a viable alternative treatment to physiotherapy in patients
with low back pain due to facet joint arthropathy. Niger J Clin
Pract 14(2):219–222. doi:10.4103/1119-3077.84021
31. Ribeiro LH, Furtado RN, Konai MS, Andreo AB, Rosenfeld A,
Natour J (2013) Effect of facet joint injection versus systemic
steroids in low back pain: a randomized controlled trial. Spine
38(23):1995–2002. doi:10.1097/BRS.0b013e3182a76df1
32. Hayes (2006) Facet blocks for chronic back pain (Structured
abstract). HAYES, Inc. http://www.crd.york.ac.uk/CRDWeb/
ShowRecord.asp?AccessionNumber=32006001570&UserID=0.
Accessed 04 June 2015
33. Kennedy DJ, Stout AA, Conrad B, Smuck M (2013) A ran-
domized, double-blind, placebo-controlled, prospective study of
intraarticular lumbar zygapophysial joint corticosteroid injec-
tion(s) as treatment of chronic low back pain in a selected pop-
ulation. Phys Med Rehabil 5(9):S286. doi:10.1016/j.pmrj.2013.
08.508
34. Machado LA, de Souza M, Ferreira PH, Ferreira ML (2006) The
McKenzie method for low back pain: a systematic review of the
literature with a meta-analysis approach. Spine 31(9):E254–
E262. doi:10.1097/01.brs.0000214884.18502.93
35. Staal JB, de Bie RA, de Vet HC, Hildebrandt J, Nelemans P
(2009) Injection therapy for subacute and chronic low back pain:
an updated Cochrane review. Spine 34(1):49–59
Eur Spine J
123
